Key Points {#FPar1}
==========

In post-stroke patients receiving antithrombotic therapy, no increased risk for bleeding complications was observed following treatment with onabotulinumtoxinAHowever, careful monitoring of the injection site immediately following onabotulinumtoxinA is warranted and patients also treated with antithrombotic therapies should be educated about the possibility for bleeding complications

Introduction {#Sec1}
============

OnabotulinumtoxinA (BOTOX^®^; Allergan plc, Dublin, Ireland) was first approved by the US Food and Drug Administration in 1989 for the treatment of blepharospasm and strabismus \[[@CR1], [@CR2]\] and is now used in many more indications. The safety and tolerability profile of onabotulinumtoxinA is well established \[[@CR3]--[@CR8]\].

OnabotulinumtoxinA is approved by the Food and Drug Administration for the treatment of upper and lower limb spasticity in adult patients to reduce the severity of increased muscle tone in elbow, wrist, finger, thumb, ankle, and toe flexors \[[@CR2]\]. According to the US labeling, it is recommended to inject onabotulinumtoxinA directly into the affected muscle using a 25- to 30-gauge needle for superficial muscles and a longer 22-gauge needle for deeper musculature \[[@CR2]\]. It is also recommended that patients inform their physicians if they are receiving antiplatelet and/or anticoagulant therapy before receiving onabotulinumtoxinA \[[@CR2]\].

Intramuscular injections may result in local bleeding, especially in patients receiving anticoagulant therapy \[[@CR9], [@CR10]\]. In particular, concerns have been raised about the potential for multiple intramuscular injections into deep compartmentalized muscles to cause acute compartment syndrome \[[@CR11], [@CR12]\]. Limited information is available regarding the safety of intramuscular medications in patients receiving oral anticoagulants even though anticoagulants are commonly used, for example, in stroke patients as a prophylaxis for recurrent stroke \[[@CR13]\]. Further, a small number of studies have suggested that onabotulinumtoxinA may affect the coagulation cascade as both acetylcholine and norepinephrine contribute to antifibrinolytic activation. It has been proposed that by binding to peripheral cholinergic nerve endings and preventing acetylcholine and norepinephrine exocytosis, onabotulinumtoxinA may prevent the formation of fibrin. Although the majority of these reports have arisen in studies in which onabotulinumtoxinA has been used to treat detrusor overactivity where local tamponade is not possible \[[@CR14]\], one case study has reported hematuria in a patient who received onabotulinumtoxin A for the treatment of upper limb spasticity \[[@CR15]\].

Recent surveys of physicians in Korea and Canada revealed considerable variability in physician practices and preferences when injecting botulinum toxin in anticoagulant-treated patients with spasticity, especially with regard to their comfort level using international normalized ratio (INR) ranges \[[@CR11], [@CR12]\]. For example, in the Korean survey, 23% of the respondents indicated that they were uncertain whether they should inject patients with botulinum toxin without knowing the INR values, and 69% of the respondents reported that they did not have any standardized protocols for performing botulinum toxin injections in patients who were receiving anticoagulants \[[@CR11]\]. The absence of clear information regarding bleeding risks and INR values associated with the injection of botulinum toxin in these patients contributes to physician uncertainty and to the wide range of approaches related to botulinum toxin injections in this population.

An audit of a small number of patients receiving stable long-term anticoagulation with warfarin (*n *= 14) who also received intramuscular botulinum toxin for spasticity showed no significant pain, tenderness, or swelling at the injection site and no major or minor bleeding after injection or during follow-up \[[@CR10]\]. However, the safety of using onabotulinumtoxinA with concomitant antiplatelet and/or anticoagulant (antithrombotic) therapy has not been reported in detail. To determine the risk of potential bleeding complications, pooled safety data from Allergan-sponsored muscle spasticity studies in which patients who were receiving concomitant antithrombotic therapy and received at least a single intramuscular injection of study drug (onabotulinumtoxinA or placebo) were analyzed. A comparison of onabotulinumtoxinA vs placebo was included in this analysis to provide context, as in the studies included in this analysis, injection paradigms for onabotulinumtoxinA and placebo groups were matched and also to delineate any effect of onabotulinumtoxinA, per se, on thrombosis. The objective of the analysis was to compare the safety of onabotulinumtoxinA vs placebo between the overall analysis population receiving antithrombotic therapy relative to those who did not.

Methods {#Sec2}
=======

This retrospective analysis included pooled safety data from Allergan-sponsored studies evaluating onabotulinumtoxinA for the treatment of patients with muscle spasticity. The analysis was further divided among those receiving intramuscular injections of either onabotulinumtoxinA or placebo with or without antithrombotic medication. The individual studies included in this analysis had appropriate ethics committee approval. The pooled data for this analysis were de-identified, thus further approval was not needed.

To be considered for this analysis, studies had to be Allergan-sponsored studies evaluating onabotulinumtoxinA in adult patients post-stroke with at least moderate upper or lower limb spasticity (*N *= 29 studies). Allergan-sponsored studies were chosen because patient-level data were available, which was not possible from non-Allergan studies. Furthermore, Allergan has access to a robust safety database based on the numerous clinical trials that have been conducted on onabotulinumtoxinA. In contrast, published studies typically report sparse information on adverse events, providing insufficient details on the use of anticoagulants in the small population of interest.

Included studies were placebo controlled in design. Studies were excluded if they were open label (*n *= 8) or if patients did not receive concomitant medication or the concomitant medication was not coded per World Health Organization terminology (*n *= 5). The remaining 16 randomized double-blind studies assessed lower limb spasticity (*n *= 9), upper limb spasticity (*n *= 5), or upper limb and/or lower limb spasticity (*n *= 2). Ten were single-cycle studies and six had at least two double-blind cycles (Study \#9/10 had up to three cycles). Upper limb muscles that were injected included wrist flexors (flexor carpi radialis and flexor carpi ulnaris), elbow flexors (biceps), and finger flexors (flexor digitorum superficialis, flexor digitorum profundus). Lower limb muscles that were injected included ankle flexors (gastrocnemius, soleus, tibialis posterior), toes (flexor digitorum longus, flexor digitorum brevis, flexor hallucis longus, extensor hallucis), and rectus femoris. Injections were delivered with appropriately sized needles depending on the depth of the musculature, with doses divided among one or more injection sites per muscle. Deep muscles were tibialis posterior, flexor digitorum longus, and flexor digitorum profundus. International normalized ratio values were not used to guide the onabotulinumtoxinA dose, and neither INR nor partial thromboplastin time data were collected. Further details of these studies, and their associated publications can be found in Table [1](#Tab1){ref-type="table"}.Table 1Description of studies included in analysisStudy IDClinicalTrials.gov IDLocation (number of centers)Study designTreatmentDuration*N* entered/*N* completedPublication**Lower limb**Study \#6NCT01575054North America, Europe, and Asia (60)Part 1: Phase III, double-blind, randomized, placebo-controlledPart 2: Open-labelPart 1: OnabotA 300--400 UPlaceboPart 2: OnabotA ≤ 400 UIM injection; ankle, plantar flexors, toe flexors/extensors, and knee flexorsPart 1: 1 treatment with 12-wk follow-upPart 2: up to 3 treatments ≥ 12-wk follow-upPart 1: OnabotA 300--400 U: 233/223Placebo: 235/227Part 2: 447/413\[[@CR26], [@CR27]\]Study \#7Europe (29)Phase II, double-blind, randomized, placebo-controlledOnabotA \~ 4 or \~ 2 U/kg ± 1 U/kgPlaceboIM injection; medial and lateral gastrocnemius ± anterior or posterior tibialisOne treatment; 12-wk follow-up4 U/kg: 45/432 U/kg: 45/44Placebo: 41/41Data included in pooled analysis: \[[@CR28]\]Study \#11/Study \#12North America (18)Phase II, double-blind, randomized, placebo-controlledOnabot \~ 4 or \~ 2 U/kgPlaceboIM injection; medial and lateral gastrocnemiusOne treatment; 24-wk follow-up4 U/kg: 33/292 U/kg: 36/33Placebo: 27/26Data included in pooled analysis: \[[@CR28]\]Study \#15Australia (7)Part 1: Phase II, double-blind, randomized, placebo-controlledPart 2: Open-labelPart 1: OnabotA 200 or 300 UPlaceboPart 2: OnabotA/OnabotA or placebo/OnabotAPart 1: 1 treatment;12- to 32-wk follow-upPart 2: 1 treatment;≥12-wk follow-upPart 1: 200 U: 28/24300 U: 28/25Placebo: 29/28Part 2:OnabotA/OnabotA: 44/38Placebo/OnabotA: 26/24\[[@CR29]\]Data included in pooled analysis: \[[@CR28]\]**Upper limb**Study \#1North America (19)Phase III, double-blind, randomized, placebo-controlledOnabotA 200--240 UPlaceboIM injections; wrist, finger flexor, and/or thumbOne treatment; 12-wk follow-up200--240 U: 64/64Placebo: 62/58\[[@CR30]\]Data included in pooled analysis: \[[@CR28]\]Study \#3North America (4)Phase II, double-blind, randomized, placebo-controlledOnabotA 200, 220, or 240 UPlaceboIM injections: wrist, finger flexors, and thumbsTwo treatments at wks 2 and 14 (30-wk follow-up)200, 220, or 240 U:22/19Placebo: 8/7Data included in pooled analysis: \[[@CR28]\]Study \#4NCT00076687North America and Europe (58)Phase II, double-blind, randomized, placebo-controlledOnabotA 240 or 360 UPlaceboIM injection upper limbsUp to two treatments over 12 or 18 wks; 1-wk follow-up after second injection240 U: 52/47360 U: 55/51Placebo: 48/42Study \#5NCT00651690North America (13)Phase II, double-blind, randomized, placebo-controlled (first treatment); open-label (second treatment)OnabotA 200--360 UPlaceboIM injections into wrist, fingers, thumb, hand, and forearm musclesTwo treatments (day 0 and either wk 2 or wk 18) over 24 wks200--360 U: 41/39Placebo: 21/20Open-label:OnabotA/OnabotA: 33/33Placebo/OnabotA: 18/15Data included in pooled analysis: \[[@CR28]\]Study \#9/Study \#10North America (19)Phase II, double-blind, randomized, dose--response, placebo-controlledOnabotA 90, 180, or 360 UPlaceboIM injection: wrist, fingers, and elbowTwo or three treatments over 24 or 36 wks, ≥ 12 wks between treatments90 U: 21/19180 U: 23/15360 U: 21/21Placebo: 26/22\[[@CR31]\]Data included in pooled analysis: \[[@CR28]\]Study \#13/Study \#14Europe (10)Phase II/III, double-blind, randomized, placebo-controlledOnabotA 90, 180, or 360 UPlaceboIM injection: wrist, fingers, and elbow muscleOne treatment; 12-wk follow-up90 U: 23/22180 U: 23/20360 U: 23/23Placebo: 20/18\[[@CR32]\]Data included in pooled analysis: \[[@CR28]\]Study \#16Asia (14)Phase III, double-blind, randomized, placebo-controlledOnabotA 200 or 240 U (thumb)PlaceboIM injection: wrist, fingers, and thumbOne treatment; 12-wk follow-up200 or 240 U: 87/82Placebo: 83/74**Upper/lower limb**Study \#2North America (12)Phase II, double-blind, randomized, placebo-controlledOnabotA 240 or 360 UPlaceboIM injections into the upper and/or lower limb musclesUp to two treatments over 18 wks, ≥ 12 wks between treatments240 U: 36/34360 U: 37/36Placebo: 36/31Data included in pooled analysis: \[[@CR28]\]Study \#8North America and Europe (34)Phase IIIb, double-blind, randomized, placebo-controlled followed by open-label extensionOnabotA + SOCPlacebo + SOCIM injections into the upper and/or lower limb musclesUp to two treatments; 34-wk follow-upOpen-label: up to four treatmentsOnabotA: 139/131Placebo: 135/122Open-label: 225/204\[[@CR33]\]\[[@CR34]\]*ID* identification, *IM* intramuscular, *OnabotA* onabotulinumtoxinA, *SOC* standard of care, *wk* week

The pooled analysis comprised all patients in the safety population, which included all who had received at least a single intramuscular injection of the study drug (onabotulinumtoxinA or placebo) during the double-blind periods. Three subgroup analyses were conducted based on the category of antithrombotic medications. In the overall antithrombotic analysis, all patients who had received concomitant treatment that may be associated with an increased risk of bleeding (based on the World Health Organization dictionary) were included. The medications selected in this antithrombotic category included: platelet aggregation inhibitors, except heparins \[*n *= 948 (80.2%)\], vitamin K antagonists \[*n *= 250 (21.2%)\], heparins \[*n *= 70 (5.9%)\], direct factor Xa inhibitors \[*n *= 4 (0.3%)\], direct thrombin inhibitors \[*n *= 3 (0.3%)\], other antithrombotic agents \[*n *= 0 (0.0%)\], and thrombolytic agents \[*n *= 0 (0.0%); Table [2](#Tab2){ref-type="table"}\]. Because platelet aggregation inhibitors (e.g., aspirin) may have a mild anticoagulant effect, a separate analysis was conducted excluding those patients who received platelet aggregation inhibitors. A third subanalysis included only heparins and vitamin K antagonists because these medications are commonly associated with bleeding complications.Table 2Concomitant antithrombotic medications by categoryCategory/medication*n* (%)Any antithrombotic medication1182 (100)Platelet aggregation inhibitors (except heparins)948 (80.2) Aspirin692 (58.5) Clopidogrel130 (11.0) Dipyridamole46 (3.9) Asasantin44 (3.7) Ticlopidine hydrochloride44 (3.7) Acetylsalicylate lysine37 (3.1) Magnyl23 (1.9) Ticlopidine11 (0.9) Cilostazol6 (0.5) Paynocil6 (0.5) Triflusal2 (0.2) Carbasalate1 (0.1)Vitamin K antagonists250 (21.2) Warfarin213 (18.0) Phenprocoumon13 (1.1) Acenocoumarol12 (1.0) Fluindione12 (1.0)Heparin group70 (5.9) Heparin37 (3.1) Enoxaparin/enoxaparin sodium20 (1.7) Nadroparin calcium4 (0.3) Certoparin sodium3 (0.3) Dalteparin sodium2 (0.2) Heparinoid2 (0.2) Nadroparin2 (0.2) Pentosan polysulfate/pentosan polysulfate sodium2 (0.2) Tinzaparin sodium1 (0.1)Direct factor Xa inhibitors4 (0.3) Rivaroxaban4 (0.3)Direct thrombin inhibitors3 (0.3) Dabigatran etexilate mesylate3 (0.3)Other antithrombotic agents0 (0.0)Thrombolytic agents0 (0.0)

Treatment-emergent adverse events (TEAEs) of interest were defined as those directly or indirectly indicating a bleeding complication and starting within 4 weeks of the first injection in the double-blind period. Injection-site reactions (bruising, discoloration, extravasation hematoma, hemorrhage, edema, or swelling), purpura, and compartment syndrome were the TEAEs of interest for this analysis.

The incidence rates for bleeding-related TEAEs across all studies were pooled to determine the overall incidence rate for bleeding-related TEAEs. Estimated pooled risk differences with 95% confidence intervals (95% CIs) were obtained using the Cochran--Mantel--Haenszel test assuming a fixed-effect model with continuity correction for zero TEAEs. Incidence rates for bleeding-related TEAEs were determined and the risk difference was calculated for patients receiving antithrombotic therapy (ATT) vs no ATT and for patients receiving intramuscular injections of onabotulinumtoxinA vs intramuscular injections of placebo (with or without ATT). Incidence rates and risk differences were also determined for all studies, upper limb, lower limb, and upper/lower limb studies.

Results {#Sec3}
=======

The analysis included 16 studies and 1877 patients, of whom 1182 received antithrombotic therapy in one of the seven overall categories. The subgroup that excluded platelet aggregation inhibitors (except heparins, six categories) included 308 patients, and the subgroup that included only vitamin K antagonists and heparins totaled 302 patients.

Demographic characteristics were generally similar in patients receiving antithrombotic therapies compared with those not receiving antithrombotic therapies, except that a greater proportion of patients receiving antithrombotic therapies were ≥ 65 years of age and Caucasian (Table [3](#Tab3){ref-type="table"}). Among patients receiving antithrombotic therapies, aspirin was the most common (59%) followed by warfarin (18%) and clopidogrel (11%; Table [2](#Tab2){ref-type="table"}).Table 3Patient demographic characteristics (safety population)CharacteristicPatients receiving any antithrombotic^a^Patients receiving any antithrombotic excluding platelet aggregation inhibitors^b^Yes (*n *= 1182)No (*n *= 695)Yes (*n *= 308)No^c^ (*n *= 1569)Mean age, years (SD)59.4 (11.7)54.8 (13.7)59.4 (12.4)57.3 (12.7)Age ≥ 65 years, *n* (%)433 (36.6)167 (24.0)123 (39.9)477 (30.4)Male, *n* (%)746 (63.1)436 (62.7)191 (62.0)991 (63.2)Race, *n* (%) Caucasian972 (82.2)467 (67.2)266 (86.4)1173 (74.8) Black74 (6.3)53 (7.6)24 (7.8)103 (6.6) Asian110 (9.3)148 (21.3)11 (3.6)247 (15.7) Hispanic20 (1.7)22 (3.2)4 (1.3)38 (2.4) Other6 (0.5)5 (0.7)3 (1.0)8 (0.5)Mean weight, kg (SD)77.5 (15.5)75.5 (15.9)79.4 (16.8)76.3 (15.4)*SD* standard deviation^a^All antithrombotic agent analysis included direct factor Xa inhibitors, direct thrombin inhibitors, heparin group, other antithrombotic agents, platelet aggregation inhibitors, thrombolytic agents, and vitamin K antagonists^b^Antithrombotic agents excluding platelet aggregation inhibitors analysis included direct factor Xa inhibitors, direct thrombin inhibitors, heparin group, other antithrombotic agents, thrombolytic agents, and vitamin K antagonists^c^Patients received none of the listed antithrombotic medications in footnote b, but may have received platelet aggregation inhibitors

Subanalysis of All Antithrombotic Agents {#Sec4}
----------------------------------------

In the cohort of patients who received an antithrombotic agent in at least one of the seven categories, the overall incidence of TEAEs that indicated a bleeding complication was \< 2% and rates were similar between those patients who received antithrombotic therapy (1.0%) and those who did not (1.4%; Table [4](#Tab4){ref-type="table"}). The risk difference (95% CI) for having a bleeding event was − 0.0042 (− 0.0148 to 0.0063) among patients who received antithrombotic therapy vs those who did not (Table [5](#Tab5){ref-type="table"}). In patients receiving antithrombotic therapy, the TEAEs that indicated a bleeding complication were injection-site bruising (0.8% overall; 0.7% in patients receiving onabotulinumtoxinA), injection-site hemorrhage (0.1% overall; none in patients receiving onabotulinumtoxinA), and purpura (0.1% overall and in patients receiving onabotulinumtoxinA). All TEAEs resolved (except one instance of injection-site bruising in a placebo recipient who was ongoing at the conclusion of the study) and none were considered serious; there were no reports of compartment syndrome.Table 4Pooled incidence of treatment-emergent adverse events of interestAdverse event, *n* (%)Analysis of all antithrombotic medications,^a^*n* (%)Antithrombotic medication (*n *= 1182)No antithrombotic medication (*n *= 695)OnabotulinumtoxinA/antithrombotic medication (*n *= 694)OnabotulinumtoxinA/no antithrombotic medication (*n *= 416)Placebo/antithrombotic medication (*n *= 488)Placebo/no antithrombotic medication (*n *= 279)Any adverse event12 (1.0)10 (1.4)6 (0.9)6 (1.4)6 (1.2)4 (1.4) Injection-site bruising10 (0.8)8 (1.2)5 (0.7)4 (1.0)5 (1.0)4 (1.4) Injection-site discoloration000000 Injection-site extravasation000000 Injection-site hematoma01 (0.1)01 (0.2)00 Injection-site hemorrhage1 (0.1)2 (0.3)01 (0.2)1 (0.2)1 (0.4) Injection-site edema000000 Injection-site swelling01 (0.1)01 (0.2)00 Purpura1 (0.1)01 (0.1)000 Compartment syndrome000000Analysis of any antithrombotic except platelet aggregation inhibitors,^b^*n* (%)Antithrombotic medication (*n *= 308)No antithrombotic medication (*n *= 1569)OnabotulinumtoxinA/antithrombotic medication (*n *= 189)OnabotulinumtoxinA/no antithrombotic medication (*n *= 921)Placebo/antithrombotic medication (*n *= 119)Placebo/no antithrombotic medication (*n *= 648)Any adverse event2 (0.6)20 (1.3)012 (1.3)2 (1.7)8 (1.2) Injection-site bruising2 (0.6)16 (1.0)09 (1.0)2 (1.7)7 (1.1) Injection-site discoloration000000 Injection-site extravasation000000 Injection-site hematoma01 (0.1)01 (0.1)00 Injection-site hemorrhage03 (0.2)01 (0.1)02 (0.3) Injection-site edema000000 Injection-site swelling01 (0.1)01 (0.1)00 Purpura01 (0.1)01 (0.1)00 Compartment syndrome000000^a^All antithrombotic agent analysis included direct factor Xa inhibitors, direct thrombin inhibitors, heparin group, other antithrombotic agents, platelet aggregation inhibitors, thrombolytic agents, and vitamin K antagonists^b^Antithrombotic medications excluding platelet aggregation inhibitors included direct factor Xa inhibitors, direct thrombin inhibitors, heparin group, other antithrombotic agents, thrombolytic agents, and vitamin K antagonistsTable 5Incidence of treatment-emergent adverse events of interest by study type and individual studyStudyAntithrombotic medication, *n/N* (%)No antithrombotic medication, *n/N* (%)Risk difference (95% CI)Patients who took antithrombotic medicationsOnabotulinumtoxinA, *n/N* (%)Placebo, *n/N* (%)Risk difference (95% CI)Analysis of all antithrombotic agents,^a^*n* (%) All studies12/1182 (1.0)10/695 (1.4)− 0.0042 (− 0.0148 to 0.0063)6/694 (0.9)6/488 (1.2)− 0.0036 (− 0.0156 to 0.0083) Lower limb studies1/532 (0.2)1/242 (0.4)− 0.0023 (− 0.0111 to 0.0066)0/304 (0)1/228 (0.4)− 0.0044 (− 0.0130 to 0.0042) Upper limb studies10/442 (2.3)1/280 (0.4)0.0191 (0.0035 to 0.0346)6/287 (2.1)4/155 (2.6)− 0.0049 (− 0.0349 to 0.0251) Lower/upper limb studies1/208 (0.5)8/173 (4.6)− 0.414 (− 0.0741 to − 0.0088)0/103 (0)1/105 (1.0)− 0.0095 (− 0.0281 to 0.0091) Study \#14/89 (4.5)1/37 (2.7)0.0179 (− 0.0498, 0.0856)2/50 (4.0)2/39 (5.1)− 0.0113 (− 0.0993, 0.0767) Study \#20/0 (0.0)8/108 (7.4)− 0.0741------ Study \#30/21 (0.0)0/9 (0.0)0.00000/15 (0.0)0/6 (0.0)0.0000 Study \#45/94 (5.3)0/61 (0.0)0.0532 (0.0078, 0.0986)3/66 (4.5)2/28 (7.1)− 0.0260 (− 0.1338, 0.0818) Study \#50/43 (0.0)0/19 (0.0)0.00000/27 (0.0)0/16 (0.0)0.0000 Study \#61/347 (0.3)1/117 (0.9)− 0.0057 (− 0.0233, 0.0119)0/175 (0.0)1/172 (0.6)− 0.0058 (− 0.0172, 0.0055) Study \#70/92 (0.0)0/39 (0.0)0.00000/61 (0.0)0/31 (0.0)0.0000 Study \#81/208 (0.5)0/65 (0.0)0.0048 (− 0.0046, 0.0142)0/103 (0.0)1/105 (1.0)− 0.0095 (− 0.0281, 0.0091) Study \#90/24 (0.0)0/8 (0.0)0.00000/19 (0.0)0/5 (0.0)0.0000 Study \#100/46 (0.0)0/13 (0.0)0.00000/30 (0.0)0/16 (0.0)0.0000 Study \#110/42 (0.0)0/19 (0.0)0.00000/33 (0.0)0/9 (0.0)0.0000 Study \#120/24 (0.0)0/11 (0.0)0.00000/15 (0.0)0/9 (0.0)0.0000 Study \#131/9 (11.1)0/2 (0.0)0.1111 (− 0.0942, 0.3164)1/9 (11.1)0/0 (0.0)0.1111 Study \#140/50 (0.0)0/27 (0.0)0.00000/37 (0.0)0/13 (0.0)0.0000 Study \#150/27 (0.0)0/56 (0.0)0.00000/20 (0.0)0/7 (0.0)0.0000 Study \#160/66 (0.0)0/104 (0.0)0.00000/34 (0.0)0/32 (0.0)0.0000Analysis of any antithrombotic medication except platelet aggregation inhibitors,^b^*n* (%) All studies2/308 (0.6)20/1569 (1.3)− 0.0063 (− 0.0168 to 0.0043)0/189 (0)2/119 (1.7)− 0.0168 (− 0.0399 to 0.0063) Lower limb studies1/121(0.8)1/653 (0.2)0.0067 (− 0.0097 to 0.0231)0/77 (0)1/44 (2.3)− 0.0227 (− 0.0668 to 0.0213) Upper limb studies1/129 (0.8)10/593 (1.7)− 0.0091 (− 0.0275 to 0.0092)0/83 (0)1/46 (2.2)− 0.0217 (− 0.0639 to 0.0204) Lower/upper limb studies0/58 (0)9/323 (2.8)− 0.0279 (-0.0458 to − 0.0099)0/29 (0)0/29 (0)0.0000 Study \#11/34 (2.9)4/92 (4.3)− 0.0141 (− 0.0845 to 0.0564)0/19 (0)1/15 (6.7)− 0.0667 (− 0.1929 to 0.0596) Study \#20/0 (0.0)8/108 (7.4)− 0.0741------ Study \#30/9 (0.0)0/21 (0.0)0.00000/7 (0)0/2 (0)0.0000 Study \#40/30 (0.0)5/125 (4.0)− 0.0400 (− 0.0744 to − 0.0056)0/19 (0)0/11 (0)0.0000 Study \#50/16 (0.0)0/46 (0.0)0.00000/7 (0)0/9 (0)0.0000 Study \#61/53 (1.9)1/411 (0.2)0.0164 (− 0.0205 to 0.0534)0/31 (0)1/22 (4.5)− 0.0455 (− 0.1325 to 0.0416) Study \#70/23 (0.0)0/108 (0.0)0.00000/14 (0)0/9 (0)0.0000 Study \#80/58 (0.0)1/215 (0.5)− 0.0047 (− 0.0137 to 0.0044)0/29 (0)0/29 (0)0.0000 Study \#90/10 (0.0)0/22 (0.0)0.00000/8 (0)0/2 (0)0.0000 Study \#100/10 (0.0)0/49 (0.0)0.00000/7 (0)0/3 (0)0.0000 Study \#110/12 (0.0)0/49 (0.0)0.00000/9 (0)0/3 (0)0.0000 Study \#120/11 (0.0)0/24 (0.0)0.00000/6 (0)0/5 (0)0.0000 Study \#130/5 (0.0)1/6 (16.7)− 0.1667 (− 0.4649 to 0.1315)0/5 (0)0/0 (0)0.0000 Study \#140/11 (0.0)0/66 (0.0)0.00000/9 (0)0/2 (0)0.0000 Study \#150/22 (0.0)0/61 (0.0)0.00000/17 (0)0/5 (0)0.0000 Study \#160/4 (0.0)0/166 (0.0)0.00000/2 (0)0/2 (0)0.0000*CI* confidence interval^a^All antithrombotic agent analysis included direct factor Xa inhibitors, direct thrombin inhibitors, heparin group, other antithrombotic agents, platelet aggregation inhibitors, thrombolytic agents, and vitamin K antagonists^b^Antithrombotic agents excluding platelet aggregation inhibitors analysis included direct factor Xa inhibitors, direct thrombin inhibitors, heparin group, other antithrombotic agents, thrombolytic agents, and vitamin K antagonists

Across all studies, the incidence of TEAEs indicating a bleeding complication in patients receiving onabotulinumtoxinA plus antithrombotic therapy was 0.9%, compared with 1.4% in patients receiving onabotulinumtoxinA and no antithrombotic therapy. Treatment-emergent adverse events indicating a bleeding complication were reported in 1.2% of patients receiving placebo plus antithrombotic therapy, and 1.4% in patients receiving placebo and no antithrombotic therapy (Table [4](#Tab4){ref-type="table"}). Among patients who received antithrombotic therapies, the risk difference (95% CI) was − 0.0036 (− 0.0156 to 0.0083; Table [5](#Tab5){ref-type="table"}) for those receiving onabotulinumtoxinA vs placebo. The incidence of TEAEs of interest by study type and also by individual study is also shown in Table [5](#Tab5){ref-type="table"}. Only patients enrolled in the upper limb studies had a higher incidence of bleeding when receiving antithrombotic therapy vs no antithrombotic therapy; the risk difference (95% CI) was 0.0191 (0.0035--0.0346). Bleeding-related TEAEs were more likely to occur in patients receiving antithrombotic therapy and receiving onabotulinumtoxinA in upper limb sites (1.9%) than those injected in lower limb sites (0.0%; Fig. [1](#Fig1){ref-type="fig"}a); similar results were reported for patients receiving antithrombotic therapy and patients receiving placebo (2.2% and 0.8%, respectively).Fig. 1Incidence of bleeding-related treatment-emergent adverse events (TEAEs) stratified by site of injection in patients receiving **a** antithrombotic treatment (ATT) and **b** anticoagulant treatment (ACT)

Subanalysis of Antithrombotic Medications Excluding Platelet Aggregation Inhibitors {#Sec5}
-----------------------------------------------------------------------------------

In the subanalysis of patients who received antithrombotic therapy but excluding platelet aggregation inhibitors (referred to herein collectively as anticoagulants), the overall incidence of TEAEs that indicated a bleeding complication was \< 2%, and rates were lower in patients who received an anticoagulant (0.6%) than in those who did not (1.3%; Table [4](#Tab4){ref-type="table"}). The risk difference (95% CI) was − 0.0063 (− 0.0168 to − 0.0043) among patients who received anticoagulant therapy vs those who did not (Table [4](#Tab4){ref-type="table"}). In patients receiving anticoagulant therapy, the only TEAE indicating a bleeding complication was injection-site bruising (0.6% overall; 0% in patients receiving onabotulinumtoxinA). All TEAEs resolved and none were deemed serious.

Across all studies, the incidence of TEAEs indicating a bleeding complication in patients receiving onabotulinumtoxinA plus anticoagulant therapy was 0%, compared with 1.3% in patients receiving onabotulinumtoxinA and no anticoagulant therapy, 1.7% in patients receiving placebo plus anticoagulant therapy, and 1.2% in patients receiving placebo and no anticoagulant therapy (Table [4](#Tab4){ref-type="table"}; Fig. [1](#Fig1){ref-type="fig"}b). Among patients who took anticoagulant therapies, the risk difference (95% CI) was − 0.0168 (− 0.0399 to 0.0063; Table [5](#Tab5){ref-type="table"}).

Only patients enrolled in the lower limb studies had a higher incidence of bleeding when receiving anticoagulant therapy vs no anticoagulant therapy (Table [5](#Tab5){ref-type="table"}). In patients receiving anticoagulant therapy, bleeding-related TEAEs were similar whether patients received onabotulinumtoxinA injections in the upper or lower limbs (0.7% vs 0.8%, respectively). Patient numbers for those being treated in the upper and lower limbs were relatively low and no bleeding-related TEAEs were reported.

Subanalysis of Heparins and Vitamin K Antagonists {#Sec6}
-------------------------------------------------

In patients who received heparins or vitamin K antagonists (*n *= 302), the incidence of TEAEs indicating a bleeding complication was 0.3% compared with 1.3% in patients who did not receive heparin or vitamin K antagonist therapy (*n *= 1575; Table [6](#Tab6){ref-type="table"}). The incidence of TEAEs indicating a bleeding complication in patients receiving onabotulinumtoxinA plus heparins or a vitamin K antagonist therapy (*n *= 188) was 0%, compared with 1.3% in patients receiving onabotulinumtoxinA and no heparin or vitamin K antagonist therapy (*n *= 922), 0.9% in patients receiving placebo plus heparin or a vitamin K antagonist (*n *= 114), and 1.4% in patients receiving placebo and no heparin or vitamin K antagonist therapy (*n *= 653).Table 6Pooled incidence of treatment-emergent adverse events of interest in patients receiving medications in heparin group or vitamin K antagonistsAdverse event, *n* (%)Antithrombotic medication (*n *= 302)No antithrombotic medication (*n *= 1575)OnabotulinumtoxinA/antithrombotic medication (*n *= 188)OnabotulinumtoxinA/no antithrombotic medication (*n *= 922)Placebo/antithrombotic medication (*n *= 114)Placebo/no antithrombotic medication (*n *= 653)Any adverse event1 (0.3)21 (1.3)012 (1.3)1 (0.9)9 (1.4) Injection-site bruising1 (0.3)17 (1.1)09 (1.0)1 (0.9)8 (1.2) Injection-site discoloration000000 Injection-site extravasation000000 Injection-site hematoma01 (0.1)01 (0.1)00 Injection-site hemorrhage03 (0.2)01 (0.1)02 (0.3) Injection-site edema000000 Injection-site swelling01 (0.1)01 (0.1)00 Purpura01 (0.1)01 (0.1)00 Compartment syndrome000000

Discussion {#Sec7}
==========

Results of this retrospective pooled safety analysis showed no increased risk of bleeding complications in patients receiving intramuscular onabotulinumtoxinA with vs without concomitant antithrombotic therapy. In all three analyses, no significant differences in the incidence of bleeding complications were observed in patients receiving onabotulinumtoxinA and concomitant antithrombotic therapy compared to those for patients receiving placebo and concomitant antithrombotic therapy, which may reflect the fact that both agents were administered in the same manner. No bleeding-related TEAEs were reported in patients receiving onabotulinumtoxinA for both upper and lower limb spasticity, but patient numbers were relatively low.

The most common bleeding complications observed overall were injection-site bruising and injection-site hemorrhage. These events were not serious and all resolved. Similar results were found in a separate analysis of patients who were receiving concomitant therapy with heparin or vitamin K antagonists (e.g., warfarin), with no increased risk of bleeding complications observed. Notably, there were no cases of compartment syndrome reported in this study. Compartment syndrome is a rare but life-threatening complication associated with minor trauma in patients receiving antithrombotic therapy \[[@CR16]\], including after a simple percutaneous needle puncture \[[@CR17]\]. Examination of the Allergan safety database revealed one post-marketing case of compartment syndrome after treatment with onabotulinumtoxinA. The case was reported in 2014; a male patient who received treatment between 2008 and 2009 experienced compartment syndrome in the calf following administration of onabotulinumtoxinA for leg spasticity. There was limited information provided, preventing further meaningful assessment. In one additional case reported in 2018, compartment syndrome was recorded in a lower limb of a patient, but the patient had received onabotulinumtoxinA for right arm spasticity, and was therefore excluded from the assessment.

Patients and clinicians should be alert for any signs of swelling, paresthesia, or pain \[[@CR17]\], particularly pain with passive stretching of the muscles \[[@CR18]\]. If any such signs are noticed, patients should be advised to seek immediate medical attention, as the time between diagnosis and treatment influences outcome \[[@CR18]\].

Limited data exist regarding the safety of administering intramuscular injections in patients receiving antithrombotic therapy. In this analysis, the incidence of bleeding complications was 1.2% in patients receiving intramuscular placebo and concomitant antithrombotic therapy, similar to that of patients receiving placebo injection without antithrombotic therapy (1.4%).

Several studies have evaluated the safety of other treatments and procedures involving the insertion of needles or pins into muscle tissues of patients receiving antithrombotic therapies. In a small retrospective chart review of Korean patients receiving warfarin (*n *= 42) or oral antiplatelet agents (*n *= 100) undergoing acupuncture, no significant adverse effects were observed compared with controls not receiving anticoagulant therapy (*n *= 100) \[[@CR19]\]. A chart review of 229 patients receiving warfarin therapy who underwent acupuncture showed that only minimal bleeding occurred at the puncture sites, with no differences observed based on INRs \[[@CR20]\]. A study of 158 patients receiving antiplatelet therapies or warfarin who underwent needle electromyography showed no greater risk of hematoma formation compared with controls \[[@CR21]\]. Likewise, in a pooled analysis of multiple studies of patients receiving anticoagulants undergoing electromyography, it was observed that the absolute risk of hematoma formation was approximately 1% \[[@CR22]\]. Overall, the results of these studies suggest no increased risk of needle muscle procedures involving piercing of muscle tissues in patients receiving oral antithrombotic therapies.

The large size of this pooled analysis (16 studies; 1877 patients, including 1182 receiving antithrombotic therapy) provided high sensitivity for detecting less common bleeding complications in patients undergoing intramuscular therapy with onabotulinumtoxinA. However, because bleeding complications are rare, the Cochran--Mantel--Haenszel test with continuity corrections to a study with zero event(s) was used. However, as has been discussed by Sweeting et al. \[[@CR23]\], this approach may be less optimal and they would suggest removing the ten zero event studies from the analyses \[[@CR23]\]. Two additional limitations of this analysis are worthy of discussion. In this study, a greater proportion of patients receiving antithrombotic therapy was ≥ 65 years of age and Caucasian, compared with those not receiving antithrombotic therapy. Whereas advanced age is a known risk for anticoagulant-associated bleeding, race has not been identified as a risk factor \[[@CR24], [@CR25]\]. Therefore, despite our population being at a relatively high risk for anticoagulant-associated bleeding compared with the population not receiving antithrombotic therapy, no difference in bleeding risk was observed. Second, while comparison of onabotulinumtoxinA to a placebo group was of interest in examining whether the injection of onabotulinumtoxinA increased the risk of bleeding complications, it should be noted that the intramuscular injection itself as well as administration of placebo (vehicle or normal saline) may potentially cause bleeding associated with mechanical trauma. Thus, the lack of comparison to a 'no intramuscular administration' group or even a 'dry needling' group could be considered a limitation of the analysis. Another limitation is that this analysis did not include non-Allergan sponsored trials and real-world studies. As the investigators of clinical trials are typically highly experienced clinicians, it is possible that the incidence of events may be higher in real-world studies that do not have the controlled environment of the clinical trial. A final limitation is that these conclusions are drawn based on data where tamponade is used as part of normal clinical practice and may not apply to situations in which tamponade cannot be applied (e.g., bladder injections, where the label provides explicit instructions regarding antiplatelet and anticoagulant therapy).

Conclusions {#Sec8}
===========

No apparent increased risk of bleeding complications was found with the administration of intramuscular onabotulinumtoxinA in a post-stroke population receiving antithrombotic therapies compared with those not receiving antithrombotic therapies. These results should be interpreted with caution as this was a retrospective pooled analysis. Careful observation of the injection site immediately following onabotulinumtoxinA and patient education regarding the potential for bleeding complications, including the signs and symptoms of compartment syndrome, when used with concomitant antithrombotic therapies are warranted.
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